Blood Coagulation Factors ; administration & dosage ; Child ; Factor IX ; administration & dosage ; Factor VIII ; administration & dosage ; Hemophilia A ; prevention & control ; therapy ; Humans

Blood Coagulation Factor Inhibitors ; antagonists & inhibitors ; blood ; Factor VIII ; administration & dosage ; antagonists & inhibitors ; immunology ; Hemophilia A ; drug therapy ; genetics ; immunology ; Humans ; Immune Tolerance ; Isoantibodies ; blood ; immunology ; Recombinant Proteins ; adverse effects ; immunology ; therapeutic use ; Risk Factors ; Time Factors

Female ; Humans ; Infant ; Leukocyte Elastase ; isolation & purification ; Neutropenia ; congenital ; enzymology

Age Distribution ; Blood Coagulation Factors ; therapeutic use ; Child ; Child, Preschool ; Developed Countries ; Developing Countries ; Factor VIII ; therapeutic use ; Hemarthrosis ; epidemiology ; etiology ; prevention & control ; Hemophilia A ; complications ; drug therapy ; epidemiology ; Humans ; Intracranial Hemorrhages ; epidemiology ; etiology ; prevention & control ; Joint Diseases ; prevention & control ; Quality of Life ; Severity of Illness Index

Adolescent ; Blood Glucose ; analysis ; Diabetes Complications ; Diabetes Mellitus ; diagnosis ; Female ; Humans ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; complications ; Treatment Outcome

Child, Preschool ; Hemophilia A ; classification ; diagnosis ; therapy ; Hemorrhage ; diagnosis ; therapy ; Humans ; Infant

This paper introduces methods to control the cost of maintenance and repair for medical equipments through service team training, service contract control, system establishment and outside service resources, etc..
Cost Control ; Equipment and Supplies ; Maintenance ; economics ; organization & administration

Objective To analyze the effectiveness of antithymocyte globulin(ATG) combined with cyclosporin(CSA)in treatment of pediatric severe aplastic anemia(SAA).Methods Seven children with SAA were treated with ATG and CSA,ATG 4-5 mg/(kg?d),5 days,methyprednisone 2-3 mg/(kg?d) to reduce anaphylaxis,CSA 3-5 mg/(kg?d),assisting with transfusion and G-CSF.Results The complete remission rate was 28.57%(2/7),the partial remission rate was 14.29%(1/7),and the obvious improvement rate was 28.57%(2/7),1 child died.The overall response rate was 71.43%.Transfusion volumes in 4 to 6 months post treatment decreased obviously comparing to the first 3 months(P